Skip to main content
Top
Published in: Diabetologia 10/2012

Open Access 01-10-2012 | Short Communication

Prevalence of monogenic diabetes amongst Polish children after a nationwide genetic screening campaign

Authors: W. Fendler, M. Borowiec, A. Baranowska-Jazwiecka, A. Szadkowska, E. Skala-Zamorowska, G. Deja, P. Jarosz-Chobot, I. Techmanska, J. Bautembach-Minkowska, M. Mysliwiec, A. Zmyslowska, I. Pietrzak, M. T. Malecki, W. Mlynarski

Published in: Diabetologia | Issue 10/2012

Login to get access

Abstract

Aims/hypothesis

The aim of this study was to study dynamic changes in the prevalence of different types of diabetes in paediatric populations in Poland, with a specific focus on monogenic diabetes (MD).

Methods

Using epidemiologic data (PolPeDiab Collaboration) and nationwide genetic test results (TEAM Programme), we compared the prevalence of type 1, type 2 and cystic fibrosis-related diabetes (CFRD) and MD. Genetically confirmed MD included MODY, neonatal diabetes and Wolfram and Alström syndromes. The study covered all children aged 0–18 years treated for diabetes between 2005 and 2011 in three regions, inhabited by 23.7% (1,989,988) of Polish children, with a low prevalence of childhood obesity (<5%).

Results

The prevalence of type 1 diabetes showed a continuous increase, from 96 to 138/100,000 children. The prevalence of type 2 diabetes and CFRD also increased, from 0.3 to 1.01/100,000 children and from 0.1 to 0.95/100,000 children, respectively. The prevalence of MD was stable at between 4.2 and 4.6/100,000 children, accounting for 3.1–4.2% of children with diabetes, with glucokinase (GCK)-MODY being the most frequent type, amounting to 83% of patients with MD. The percentage of positive test results decreased with the number of referrals, suggesting that children with the highest probability of MD were referred initially, followed by those with a less clear-cut phenotype. The prevalence of neonatal diabetes equalled 1 in 300,000 children.

Conclusions/interpretation

The prevalence of MD in a paediatric population with a low prevalence of obesity remains stable and is nearly fivefold higher than that of type 2 diabetes and CFRD, justifying a need for increased access to genetic diagnostic procedures in diabetic children.
Appendix
Available only for authorised users
Literature
1.
go back to reference Neu A, Feldhahn L, Ehehalt S, Hub R, Ranke MB (2009) Type 2 diabetes mellitus in children and adolescents is still a rare disease in Germany: a population-based assessment of the prevalence of type 2 diabetes and MODY in patients aged 0–20 years. Pediatr Diabetes 10:468–473PubMedCrossRef Neu A, Feldhahn L, Ehehalt S, Hub R, Ranke MB (2009) Type 2 diabetes mellitus in children and adolescents is still a rare disease in Germany: a population-based assessment of the prevalence of type 2 diabetes and MODY in patients aged 0–20 years. Pediatr Diabetes 10:468–473PubMedCrossRef
2.
go back to reference Amed S, Dean HJ, Panagiotopoulos C et al (2010) Type 2 diabetes, medication-induced diabetes, and monogenic diabetes in Canadian children: a prospective national surveillance study. Diabetes Care 33:786–791PubMedCrossRef Amed S, Dean HJ, Panagiotopoulos C et al (2010) Type 2 diabetes, medication-induced diabetes, and monogenic diabetes in Canadian children: a prospective national surveillance study. Diabetes Care 33:786–791PubMedCrossRef
3.
go back to reference Shields BM, Hicks S, Shepherd MH, Colclough K, Hattersley AT, Ellard S (2010) Maturity-onset diabetes of the young (MODY): how many cases are we missing? Diabetologia 53:2504–2508PubMedCrossRef Shields BM, Hicks S, Shepherd MH, Colclough K, Hattersley AT, Ellard S (2010) Maturity-onset diabetes of the young (MODY): how many cases are we missing? Diabetologia 53:2504–2508PubMedCrossRef
4.
go back to reference Jarosz-Chobot P, Polanska J, Szadkowska A et al (2011) Rapid increase in the incidence of type 1 diabetes in Polish children from 1989 to 2004, and predictions for 2010 to 2025. Diabetologia 54:508–515PubMedCrossRef Jarosz-Chobot P, Polanska J, Szadkowska A et al (2011) Rapid increase in the incidence of type 1 diabetes in Polish children from 1989 to 2004, and predictions for 2010 to 2025. Diabetologia 54:508–515PubMedCrossRef
5.
go back to reference Borowiec M, Fendler W, Antosik K et al (2011) Doubling the referral rate of monogenic diabetes through a nationwide information campaign – update on glucokinase gene mutations in a Polish Cohort. Clin Genet 2011. doi:10.1111/j.1399-0004.2011.01803.x Borowiec M, Fendler W, Antosik K et al (2011) Doubling the referral rate of monogenic diabetes through a nationwide information campaign – update on glucokinase gene mutations in a Polish Cohort. Clin Genet 2011. doi:10.​1111/​j.​1399-0004.​2011.​01803.​x
6.
go back to reference Ottova V, Erhart M, Rajmil L, Dettenborn-Betz L, Ravens-Sieberer U (2012) Overweight and its impact on the health-related quality of life in children and adolescents: results from the European KIDSCREEN survey. Qual Life Res 21(1):59–69PubMedCrossRef Ottova V, Erhart M, Rajmil L, Dettenborn-Betz L, Ravens-Sieberer U (2012) Overweight and its impact on the health-related quality of life in children and adolescents: results from the European KIDSCREEN survey. Qual Life Res 21(1):59–69PubMedCrossRef
7.
go back to reference Ellard S, Bellanne-Chantelot C, Hattersley AT (2008) Best practice guidelines for the molecular genetic diagnosis of maturity-onset diabetes of the young. Diabetologia 51:546–553PubMedCrossRef Ellard S, Bellanne-Chantelot C, Hattersley AT (2008) Best practice guidelines for the molecular genetic diagnosis of maturity-onset diabetes of the young. Diabetologia 51:546–553PubMedCrossRef
8.
go back to reference Slingerland AS, Shields BM, Flanagan SE et al (2009) Referral rates for diagnostic testing support an incidence of permanent neonatal diabetes in three European countries of at least 1 in 260,000 live births. Diabetologia 52:1683–1685PubMedCrossRef Slingerland AS, Shields BM, Flanagan SE et al (2009) Referral rates for diagnostic testing support an incidence of permanent neonatal diabetes in three European countries of at least 1 in 260,000 live births. Diabetologia 52:1683–1685PubMedCrossRef
9.
go back to reference Pruhova S, Ek J, Lebl J et al (2003) Genetic epidemiology of MODY in the Czech republic: new mutations in the MODY genes HNF-4alpha, GCK and HNF-1alpha. Diabetologia 46:291–295PubMed Pruhova S, Ek J, Lebl J et al (2003) Genetic epidemiology of MODY in the Czech republic: new mutations in the MODY genes HNF-4alpha, GCK and HNF-1alpha. Diabetologia 46:291–295PubMed
10.
go back to reference Pearson ER, Velho G, Clark P et al (2001) Beta-cell genes and diabetes: quantitative and qualitative differences in the pathophysiology of hepatic nuclear factor-1alpha and glucokinase mutations. Diabetes 50(Suppl 1):S101–S107PubMedCrossRef Pearson ER, Velho G, Clark P et al (2001) Beta-cell genes and diabetes: quantitative and qualitative differences in the pathophysiology of hepatic nuclear factor-1alpha and glucokinase mutations. Diabetes 50(Suppl 1):S101–S107PubMedCrossRef
11.
go back to reference Moran A, Dunitz J, Nathan B, Saeed A, Holme B, Thomas W (2009) Cystic fibrosis-related diabetes: current trends in prevalence, incidence, and mortality. Diabetes Care 32:1626–1631PubMedCrossRef Moran A, Dunitz J, Nathan B, Saeed A, Holme B, Thomas W (2009) Cystic fibrosis-related diabetes: current trends in prevalence, incidence, and mortality. Diabetes Care 32:1626–1631PubMedCrossRef
Metadata
Title
Prevalence of monogenic diabetes amongst Polish children after a nationwide genetic screening campaign
Authors
W. Fendler
M. Borowiec
A. Baranowska-Jazwiecka
A. Szadkowska
E. Skala-Zamorowska
G. Deja
P. Jarosz-Chobot
I. Techmanska
J. Bautembach-Minkowska
M. Mysliwiec
A. Zmyslowska
I. Pietrzak
M. T. Malecki
W. Mlynarski
Publication date
01-10-2012
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 10/2012
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-012-2621-2

Other articles of this Issue 10/2012

Diabetologia 10/2012 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.